Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid

Article Abstract:

The precise mechanism of action of Isoniazid, the most effective antituberculosis drug, is yet to be configured. A study conducted by using specialized linkage transduction to transfer a single point mutation allele (S94A) within the putative target gene inhA in Mycobacterium tuberculosis found that the inhA(S94A) was sufficient to confer clinically relevant levels of resistance to isonizad killing and inhibition of mycolic acid biosynthesis and establishes InhA as the primary target of isoniazid action in M. tuberculosis.

Author: Sacchettini, James C., Vilcheze, Catherine, Jacobs, William R., Jr., Feng Wang, Kremer, Laurent, Arai, Masayoshi, Hazbon, Manzour Hernando, Colangeli, Roberto, Weisbrod, Torin R., Alland, David
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2006
Drug therapy, Mycobacterium tuberculosis, Isoniazid (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The open book of infectious diseases

Article Abstract:

New antitubercular compounds belonging to chemical classes that are newly exploited along with more efficient methods to identify drug targets have produced exciting developments in antituberculosis antibiotics. The impact of new drugs, which are still in clinical trial stages, on the treatment of infectious diseases is discussed.

Author: Rubin, Eric J., Sassetti, Christopher M.
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
Communicable diseases, Antiviral agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


From magic bullets back to the Magic Mountain: The rise of extensively drug-resistant tuberculosis

Article Abstract:

An integrated approach is required for tackling the problem of extensively drug-resistant tuberculosis (XDR-TB) in high HIV prevalence settings. The World Health Organization's (WHO's) recommendations for controlling XDR-TB and also the development in research and development of the drugs for preventing TB are discussed.

Author: Chaisson, Richard E., Dorman, Susan E.
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
Government domestic functions, Risk factors, Tuberculosis, World Health Organization, Health policy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States, Antitubercular agents, Prevention
Similar abstracts:
  • Abstracts: New opportunities on the horizon. Nice guidelines for tuberculosis: Will they help improve practice?. A review of the literature on the nurse role in clinical audit
  • Abstracts: Delaying generic competition - Corporate payoffs and the future of Plavix. Approving the vagus-nerve stimulator for depression
  • Abstracts: The role of branding in dental practice marketing. What are my ethical responsibilities when I suspect an employee of substance abuse?
  • Abstracts: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. New approaches to antidepressant drug discovery: beyond monoamines
  • Abstracts: AIDS meeting spotlights pills to prevent infection. The sunshine cure
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.